Moody's Rating for Can Fite Biopharma

MOODY'S ANALYTICS RISK SCORE

8

Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical company, which focuses on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases. Its products include pipeline drugs such as CF101, CF102 and CF602. The company offers drugs for the treatment of Psoriasis, Rheumatic Arthritis, Glaucoma, Uveitis, Crohn's disease, Osteoathritis, Hepatitis C, and Liver Cancer. Can-Fite BioPharma was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach Tikva, Israel.